Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC, VI, and UMEC/VI crossover lung function study in COPD
2011-005913-35Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Weighted mean FEV1 over 0-6 hours post-dose on Day 14. Started Mar 2016; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-005913-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005913-35.